Welcome to our dedicated page for Azenta SEC filings (Ticker: AZTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Azenta, Inc.'s SEC filings document operating results, material events, governance matters and acquisition agreements for a life sciences solutions company built around cold-chain sample management and multiomics services. Recent Form 8-K disclosures include quarterly results and financial-condition updates, leadership and board changes, and the material definitive agreement under which Azenta UK Ltd acquired UK Biocentre.
The company’s proxy and annual-meeting filings describe director elections, advisory executive-compensation votes, equity incentive plan amendments and auditor ratification. Together with material-event reports, these filings provide formal disclosure on Azenta’s governance structure, capital-related authorizations, transaction terms and recurring public-company reporting obligations.
Azenta, Inc. director Robyn C. Davis received a grant of 5,663 restricted stock units on Azenta common stock on February 5, 2026. Each unit represents one share of common stock and was granted at a price of $0. The units are fully vested upon grant.
Davis elected to defer settlement of these units until the later of reaching age 65 or separating from service with the company. After this award, Davis beneficially owns 23,662 derivative securities in the form of restricted stock units, granted under Azenta’s 2020 Equity Incentive Plan.
Azenta, Inc. reported a net loss of $15.4M for the quarter ended December 31, 2025, compared with a loss of $11.0M a year earlier. Total revenue from continuing operations was broadly flat at $148.6M, with Sample Management Solutions at $81.4M and Multiomics at $67.2M.
Continuing operations generated a loss of $5.2M, while discontinued operations, mainly the B Medical Systems business, added a further loss of $10.2M. Azenta recorded a $9.7M loss on assets held for sale as it moves toward divesting B Medical.
Under a Share Purchase Agreement signed with Thelema S.À R.L., B Medical Systems is being sold for $63.0M. Thelema has paid a $9.0M deposit, with the remaining $54.0M due on or before March 31, 2026, subject to Thelema obtaining final financing; if this fails, Azenta retains $5.0M as a break-up fee.
Azenta ended the quarter with $336.6M in cash and cash equivalents, plus $228.9M in marketable securities, and total assets of $2.07B against liabilities of $359.6M. The company continues its 2024 restructuring program and has a new $250M share repurchase authorization through December 31, 2028, with no buybacks yet executed.
Azenta, Inc. announced its financial results for the fiscal quarter ended December 31, 2025 through a press release dated February 4, 2026. The company furnished this release as Exhibit 99.1, rather than treating it as formally filed for liability purposes. The disclosure also highlights that the release contains forward-looking statements and directs readers to the cautionary note in the press release for a discussion of related risks and uncertainties.
Azenta, Inc. reported that Alan P. Malus resigned from its Board of Directors, effective January 29, 2026. He also stepped down from his role on the Human Resources and Compensation Committee.
The company stated that his resignation was not due to any disagreement over operations, policies, or practices. Instead, he accepted full-time responsibilities with another company, which will limit the time he can devote to Azenta board duties.
Azenta, Inc. held its Annual Meeting of stockholders on January 28, 2026, where investors approved several key proposals. Stockholders elected all nominated directors to the board, with each nominee receiving a substantial majority of votes cast.
Stockholders approved, on a non-binding advisory basis, the overall compensation of Azenta’s named executive officers. They also approved an amendment to the Company’s 2020 Equity Incentive Plan to increase the number of shares reserved for issuance by 2,750,000, expanding the pool available for future equity awards. In addition, stockholders ratified the appointment of PricewaterhouseCoopers LLP as Azenta’s independent registered public accounting firm for the 2026 fiscal year.
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting beneficial ownership of 2,099,441 Azenta Inc common shares, representing 4.6% of the outstanding class as of the reported date. Dimensional has sole power to vote 2,061,526 shares and sole power to dispose of 2,099,441 shares.
The shares are held across various funds and accounts for which Dimensional or its subsidiaries act as adviser or manager, and all securities are owned by those funds rather than by Dimensional itself. Dimensional states that the holdings are maintained in the ordinary course of business and are not intended to change or influence control of Azenta.
Azenta, Inc. is asking shareholders to vote at a virtual-only annual meeting on January 28, 2026, with a record date of December 3, 2025. Shareholders will elect ten directors, hold an advisory vote on executive pay, approve an increase of 2,750,000 shares reserved under the 2020 Equity Incentive Plan, and ratify PricewaterhouseCoopers LLP as independent auditor for fiscal 2026.
The board is led by an independent chair, and nine of ten director nominees are independent, with an average tenure of 2.7 years and 40% gender, racial or ethnic diversity. Azenta highlights ESG oversight, board refreshment, and strong governance practices, including annual say-on-pay and stock ownership guidelines. The company reports fiscal 2025 revenue growth of 4% (3% organic) and 310 basis points of margin expansion, and is pursuing a sale of its B Medical business, which has been reclassified as discontinued operations.
Azenta, Inc. (AZTA) reported an equity award to its President and CEO, John Marotta. On 11/24/2025 he received a grant of 122,269 restricted stock units (RSUs) of Azenta common stock at a price of $0.00 per unit, recorded as an acquisition of non-derivative securities. Following this grant, he beneficially owns 217,268.78 shares of common stock.
The RSU award was sized by dividing a target award value by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date. These RSUs are subject to time-based vesting, with 33-1/3% of the units scheduled to vest each year, beginning on November 24, 2026.
Azenta, Inc. (AZTA) executive Lawrence Y. Lin reported an equity award of company stock. On 11/24/2025, the EVP, CFO and Treasurer received a grant of 36,681 restricted stock units (RSUs) of Azenta common stock at a price of $0.00 per unit. Following this grant, he beneficially owns 79,655 shares of Azenta common stock in total, held directly.
The RSUs are subject to time-based vesting and are scheduled to vest in three equal annual installments of 33-1/3% each year, beginning on November 24, 2026. The number of RSUs granted was calculated by dividing a target award value by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date.
Azenta, Inc. (AZTA) reported an equity compensation grant to one of its senior executives. On November 24, 2025, the company granted 16,303 restricted stock units (RSUs) of its common stock to its SVP and Chief Human Resources Officer, Olga Pirogova, with no cash paid upon grant and a stated price of $0.00 per unit.
The filing states that the number of RSUs was determined by dividing the target award value by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date. These RSUs are subject to time-based vesting, with 33 1/3% vesting each year beginning on November 24, 2026. Following this grant, the reporting person beneficially owns 33,038 shares of Azenta common stock.